4//SEC Filing
Martin Tami Tillotson 4
Accession 0001104659-24-003741
CIK 0001356576other
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 5:00 PM ET
Size
9.6 KB
Accession
0001104659-24-003741
Insider Transaction Report
Form 4
Martin Tami Tillotson
VP of Regulatory Affairs
Transactions
- Exercise/Conversion
Employee Stock Option (Right to Buy)
2024-01-10−8,000→ 0 totalExercise: $9.24Exp: 2024-01-21→ Common Stock (8,000 underlying) - Exercise/Conversion
Common Stock
2024-01-10$9.24/sh+8,000$73,920→ 93,664 total - Sale
Common Stock
2024-01-10$27.91/sh−8,000$223,280→ 85,664 total
Footnotes (4)
- [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.
- [F2]Includes an aggregate of 415 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.69 to $28.22, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F4]The option vested in four equal annual installments beginning on January 21, 2015.
Documents
Issuer
SUPERNUS PHARMACEUTICALS, INC.
CIK 0001356576
Entity typeother
Related Parties
1- filerCIK 0001539494
Filing Metadata
- Form type
- 4
- Filed
- Jan 11, 7:00 PM ET
- Accepted
- Jan 12, 5:00 PM ET
- Size
- 9.6 KB